Jane Street Group, LLC Nektar Therapeutics Call Options Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	SELL	$4.16 - $13.72 $80,704 - $266,168	-19,400 Reduced 4.58%	404,600 $2.18 Million
Q4 2021 Feb 15, 2022	BUY	$10.83 - $18.41 $1.07 Million - $1.82 Million	98,700 Added 30.34%	424,000 $5.73 Million
Q3 2021 Nov 16, 2021	BUY	$13.07 - $18.84 $1.55 Million - $2.24 Million	118,800 Added 57.53%	325,300 $5.84 Million
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $2.79 Million - $3.45 Million	168,900 Added 449.2%	206,500 $3.54 Million
Q1 2021 May 18, 2021	SELL	$16.56 - $25.46 $165,600 - $254,600	-10,000 Reduced 21.01%	37,600 $752,000
Q4 2020 Feb 17, 2021	SELL	$15.77 - $19.03 $766,422 - $924,858	-48,600 Reduced 50.52%	47,600 $809,000
Q3 2020 Nov 17, 2020	SELL	$16.59 - $24.79 $310,233 - $463,573	-18,700 Reduced 16.28%	96,200 $1.6 Million
Q2 2020 Aug 17, 2020	BUY	$16.86 - $23.44 $1.05 Million - $1.46 Million	62,100 Added 117.61%	114,900 $2.66 Million
Q2 2018 Aug 15, 2018	BUY	$46.25 - $104.45 $2.15 Million - $4.85 Million	46,400 Added 725.0%	52,800 $2.58 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $109,060 - $206,036	1,900 Added 42.22%	6,400 $680,000
Q4 2017 Feb 15, 2018	BUY	$23.02 - $60.5 $103,590 - $272,250	4,500	4,500 $269,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $156M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.